Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy.

Wimmers F, Aarntzen EH, Schreibelt G, Jacobs JF, Ja Punt C, Figdor CG, de Vries IJ.

Oncoimmunology. 2014 Jan 1;3(1):e27219.

2.

Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.

Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, Adema GJ, Figdor CG, Punt CJ, De Vries IJ.

Cancer Res. 2012 Dec 1;72(23):6102-10. doi: 10.1158/0008-5472.CAN-12-2479. Epub 2012 Sep 24.

3.

Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.

de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ.

J Clin Oncol. 2005 Aug 20;23(24):5779-87.

PMID:
16110035
4.

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.

Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12.

5.

Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.

Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ.

Clin Cancer Res. 2012 Oct 1;18(19):5460-70. doi: 10.1158/1078-0432.CCR-11-3368. Epub 2012 Aug 15.

6.

Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.

Berger TG, Haendle I, Schrama D, Lüftl M, Bauer N, Pedersen LØ, Schuler-Thurner B, Hohenberger W, Straten Pt Pt, Schuler G, Becker JC.

Int J Cancer. 2004 Aug 20;111(2):229-37.

7.

Immunomonitoring in glioma immunotherapy: current status and future perspectives.

Lamano JB, Ampie L, Choy W, Kesavabhotla K, DiDomenico JD, Oyon DE, Parsa AT, Bloch O.

J Neurooncol. 2016 Mar;127(1):1-13. doi: 10.1007/s11060-015-2018-4. Epub 2015 Dec 5. Review.

8.

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.

Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L.

Br J Cancer. 2001 Dec 14;85(12):1871-7.

9.

Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.

Zikich D, Schachter J, Besser MJ.

Immunotherapy. 2016;8(1):35-43. doi: 10.2217/imt.15.99. Epub 2015 Dec 10. Review.

PMID:
26653685
10.

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.

Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P.

Clin Cancer Res. 2006 Oct 1;12(19):5801-8.

11.

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

J Immunol Methods. 2012 Mar 30;377(1-2):23-36. doi: 10.1016/j.jim.2011.12.010. Epub 2012 Jan 16.

PMID:
22269772
12.

Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ.

Oncoimmunology. 2015 Aug 12;5(1):e1067745. eCollection 2016.

13.

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts.

Mackensen A, Veelken H, Lahn M, Wittnebel S, Becker D, Köhler G, Kulmburg P, Brennscheidt U, Rosenthal F, Franke B, Mertelsmann R, Lindemann A.

J Mol Med (Berl). 1997 Apr;75(4):290-6.

PMID:
9151215
14.

Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.

Waanders GA, Rimoldi D, Liénard D, Carrel S, Lejeune F, Dietrich PY, Cerottini JC, Romero P.

Clin Cancer Res. 1997 May;3(5):685-96.

15.
16.

The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.

Oosterhoff D, Sluijter BJ, Hangalapura BN, de Gruijl TD.

Curr Top Microbiol Immunol. 2012;351:181-220. doi: 10.1007/82_2011_136. Review.

PMID:
21681685
17.

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA.

Cancer Res. 1994 Jun 15;54(12):3124-6. Erratum in: Cancer Res 1994 Jul 15;54(14):3952.

18.

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ.

Lancet Oncol. 2012 Jan;13(1):e32-42. doi: 10.1016/S1470-2045(11)70155-3. Review.

PMID:
22225723
19.

Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.

Nakai N, Katoh N, Germeraad WT, Kishida T, Ueda E, Takenaka H, Mazda O, Kishimoto S.

J Dermatol Sci. 2009 Jan;53(1):40-7. doi: 10.1016/j.jdermsci.2008.07.013. Epub 2008 Sep 19.

PMID:
18804963
20.

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10.

Supplemental Content

Support Center